Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
Recruiting
Observational Study
Malaria
PLASMODIUM FALCIPARUM MALARIA
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 5 Months – 5
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20,000 (estimated)
- Sponsor
- Clinton Health Access Initiative Inc. · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and are eligible for the national R21/Matrix-M vaccination program will be enrolled. Malaria infection will be determined b…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Residence in an area where R21/Matrix-M is implemented and within the catchment area of a selected study facility.
* Younger than 5 years and eligibleto receive R21/Matrix-M under the national vaccination schedule at rollout.
* Meets the country definition of suspected malaria…
Contacts
No contact information available.